RX fundamentals
An in-depth look to BIOSYENT INC operating, investing, and financing activities
RX free cash flow for Q2 24 is -1.02 M CAD. For 2023, RX free cash flow was 5.77 M CAD and operating cash flow was 5.83 M CAD.
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: CAD
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
TTM